Found: 4
Select item for more details and to access through your institution.
Beta-Arrestin 2 Is Required for Dopamine Receptor Type 2 Inhibitory Effects on AKT Phosphorylation and Cell Proliferation in Pituitary Tumors.
- Published in:
- Neuroendocrinology, 2021, v. 111, n. 6, p. 568, doi. 10.1159/000509219
- By:
- Publication type:
- Article
Cytoskeleton Protein Filamin A Is Required for Efficient Somatostatin Receptor Type 2 Internalization and Recycling through Rab5 and Rab4 Sorting Endosomes in Tumor Somatotroph Cells.
- Published in:
- Neuroendocrinology, 2020, v. 110, n. 7/8, p. 642, doi. 10.1159/000503791
- By:
- Publication type:
- Article
Stem Cells in Pituitary Tumors: Experimental Evidence Supporting Their Existence and Their Role in Tumor Clinical Behavior.
- Published in:
- Frontiers in Endocrinology, 2019, v. 10, p. 1, doi. 10.3389/fendo.2019.00745
- By:
- Publication type:
- Article
Dopamine and Somatostatin Analogues Resistance of Pituitary Tumors: Focus on Cytoskeleton involvement.
- Published in:
- Frontiers in Endocrinology, 2015, v. 6, p. 1, doi. 10.3389/fendo.2015.00187
- By:
- Publication type:
- Article